{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '8.4.2', 'Method of Detecting Adverse Events and Serious Adverse Events', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and', 'non-leading verbal questioning of the subject is the preferred method to inquire about', 'AE occurrences.', '8.4.3', 'Follow-Up of Adverse Events and Serious Adverse Events', 'After the initial AE/SAE report, the Investigator is required to proactively follow each subject at', 'subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is', 'otherwise explained, or the subject is lost to follow-up (as defined in Section 7.6). Further', 'information on follow-up procedures is given in Appendix 4.', '8.4.4', 'Regulatory Reporting Requirements for Serious Adverse Events', 'Prompt notification by the Investigator to the Sponsor of an SAE is essential so that legal', 'obligations and ethical responsibilities towards the safety of subjects and the safety of a study', 'treatment under clinical investigation are met.', 'The Sponsor has a legal responsibility to notify both the local regulatory authority and other', 'regulatory agencies about the safety of a study treatment under clinical investigation. The Sponsor', 'will comply with country-specific regulatory requirements relating to safety reporting to the', 'regulatory authority, Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs),', 'and Investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious adverse reactions', \"(SUSARs) according to local regulatory requirements and the Sponsor's policy and forwarded to\", 'the Investigators as necessary.', 'An Investigator who receives an Investigator safety report describing an SAE or other specific', 'safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it', \"along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to\", 'local requirements.', '8.4.5', 'Pregnancy', 'A UPT will be performed at Visit 2 (Baseline), Visit 4, Visit 5, and Visit 6 (EOS) for WOCBP.', 'Women who are pregnant or breastfeeding may not be administered TMB-001 ointment.', 'If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of learning', 'of the pregnancy and should follow the procedures outlined in Appendix 6.', 'Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital', 'anomalies, ectopic pregnancy) are considered SAEs.', '43']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '8.4.6', 'Adverse Events of Special Interest', 'No events will be considered as AEs of special interest for this study.', '8.4.7', 'Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as', 'Adverse Events or Serious Adverse Events', 'Disease attributes that are associated with underlying disease condition should not be reported as', 'AEs. Local skin reactions associated with retinoids should not be reported as AEs unless the LSRs', 'required medical intervention or withholding application of study medication (refer Section 8.3.3', 'for complete details).', '8.5', 'Treatment of Overdose', 'Overdose in this study can be defined as either oral ingestion of a tube of TMB-001 or applying', 'the TMB-001 ointment more than the protocol specified regimen of twice daily.', 'Oral ingestion of a tube of TMB-001 ointment 0.1% would result in less exposure than achieved', 'with the recommended dosage of oral isotretinoin. Consequently, the theoretical occurrence of', 'symptoms of overdosage (eg, hypervitaminosis A) is highly unlikely.', 'If a subject does receive an overdose of TMB-001 ointment, the subject should be counseled about', 'the teratogenicity of isotretinoin and counseled on the prevention of pregnancy. Any WOCBP must', 'be evaluated for pregnancy and must be warned to avoid pregnancy per the contraceptive measures', 'outlined in the protocol for at least 1 month after overdose. Men should use a condom or avoid', 'reproductive sexual activity with a female who is or might become pregnant for at least 1 month', 'after an overdose. Subjects who present with an overdose should not donate blood for at least', '1 month.', 'In the event of an overdose, the Investigator should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the subject for any AEs, SAEs, and laboratory abnormalities for 1 month', 'after the overdose.', '3. Obtain a plasma sample for pharmacokinetic analysis if requested by the Medical Monitor', '(determined on a case-by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdose in the', 'eCRF.', 'Decisions regarding dose interruptions or modifications will be made by the Investigator in', 'consultation with the Medical Monitor based on the clinical evaluation of the subject.', '44']\n\n###\n\n", "completion": "END"}